Gemcitabine Degradation in Whole Blood from Humans, Dogs, Cats, and Horses
- *Corresponding Author:
- Carlos O Rodriguez Jr
Department of Veterinary Surgical and Radiological Sciences
University of California-Davis, Davis, USA
E-mail: [email protected]
Received date: July 09, 2012; Accepted date: August 23, 2012; Published date: August 25, 2012
Citation: O’Brien DR, Guerrero TA, Frazier SA, Rebhun RB, Skorupski KA, et al. (2012) Gemcitabine Degradation in Whole Blood from Humans, Dogs, Cats, and Horses. J Vet Sci Technol 3:119. doi:10.4172/2157-7579.1000119
Copyright: © 2012 O’Brien DR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The purpose of this in vitro study was to compare the degradation of gemcitabine (2’, 2’-difluorodeoxycytidine, dFdC), in Fresh Whole Blood (FWB) from humans, dogs, cats, and horses. A better understanding of the comparative degradation of gemcitabine may aid in the optimal design of therapeutic regimens in veterinary species. Fresh whole blood from humans, dogs, cats, and horses was spiked with dFdC and plasma was analyzed for dFdC and 2’, 2’-difluorodeoxyuridine (dFdU) by high performance liquid chromatography. In these species, there was an initial rapid degradation of dFdC with a concomitant proportional increase in dFdU. Degradation of gemcitabine appeared similar in humans, dogs, and horses (p>0.05) whereas metabolism was slower in the cat than human (p=0.014), dog (p=0.010), or horse (p=0.0015). Based on these in vitro findings, dosing schemes for humans, dogs, and horses may be similar. In contrast, gemcitabine degradation occurred more slowly in the cat; this difference may dictate a different dosing scheme for optimal response in this species.